Current Atherosclerosis Reports

, Volume 13, Issue 3, pp 187–189 | Cite as

Systemic Inflammation and the Dynamics of HDL Cholesterol–Associated Residual Cardiovascular Risk

Clinical Trial Report


  1. 1.
    Fruchart JC, Sacks F, Hermans MP, et al. Executive statement, the residual risk reduction initiative: a call to action to reduce residual vascular risk in dyslipidemic patients. Diab Vasc Dis Res. 2008;5:319–35.PubMedCrossRefGoogle Scholar
  2. 2.
    Barter P, Gotto AM, LaRosa JC, et al. HDL-cholesterol, very low levels of LDL-cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301–10.PubMedCrossRefGoogle Scholar
  3. 3.
    Rosenson RS. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy. Am Heart J. 2006;151:556–63.PubMedCrossRefGoogle Scholar
  4. 4.
    West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1998;97:1440–5.Google Scholar
  5. 5.
    Ridker PM, Gesest J, Boekholdt SM, et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet. 2010;376:333–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.PubMedCrossRefGoogle Scholar
  7. 7.
    Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL-cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE-IT TIMI 22. Arterioscler Thromb Vasc Biol. 2009;29:424–30.PubMedCrossRefGoogle Scholar
  8. 8.
    Seeger JD, Walker AM, Williams PL, Saperia GM, Sacks FM. A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction. Am J Cardiol. 2003;92:1447–51.PubMedCrossRefGoogle Scholar
  9. 9.
    Rosenson RS, Davidson MH, Pourfazib R. Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic risk. Atherosclerosis. 2010;213:1–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Rosenson RS, Otvos JD, Hsia J. Effects of rosuvastatin and atorvastatin on low-density and high-density lipoprotein particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. Diabetes Care. 2009;32:1087–91.PubMedCrossRefGoogle Scholar
  11. 11.
    Gotto AM, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000;101:477–84.PubMedGoogle Scholar
  12. 12.
    Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation. 2006;113:1556–63.PubMedCrossRefGoogle Scholar
  13. 13.
    Vaiser T, Pennathur S, Greene PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the anti-inflammatory properties of HDL. J Clin Invest. 2007;117:595–8.CrossRefGoogle Scholar
  14. 14.
    Rosenson RS. Functional assessment of HDL: Moving beyond static measures for risk assessment. Cardiovas Drugs Ther. 2010;24:71–5.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Mount Sinai HeartMount Sinai School of MedicineNew YorkUSA

Personalised recommendations